NYSE$JNJ

Johnson & Johnson · Q1 2025 earnings

Q1 2025 earnings · · Before market open · Investor relations

Briefing

Johnson & Johnson reported Q1 2025 sales of $21.9B with net earnings of $11.0B and diluted EPS of $4.54.

Worldwide sales were $21.9 billion for the quarter ended March 30, 2025, up 2% year over year. Net earnings were $11.0 billion ($4.54 diluted EPS) versus $3.3 billion ($1.34) a year ago, lifted by a large non-cash gain in other income tied to the Intra-Cellular Therapies acquisition. Innovative Medicine and MedTech remained the growth engines; the board raised the quarterly dividend to $1.30.

  • Q1 sales $21.9B (+2% YoY); diluted EPS $4.54.
  • Net earnings $11.0B includes significant acquisition-related other income.
  • Intra-Cellular acquisition closed after quarter-end (~$14.6B).
  • Dividend increased to $1.30 per share for June 2025 payment.

Headline financials

Total Revenue

$21.9B

Previous: $21.4B+2.4%
EPS (adj)

$4.54

Previous: $1.34+238.8%
Capital Expenditures

-$795M

Previous: -$807M+1.5%
Free Cash Flow

$3.4B

Previous: $2.45B+38.9%
Net Income

$11B

Previous: $3.26B+237.9%
Operating Income

$13.6B

Previous: $4.62B+194.8%
Gross Profit

$14.5B

Previous: $14.9B-2.3%
R&D Expense

$3.23B

Previous: $3.54B-8.9%

Revenue & EPS history

Johnson & Johnson · Revenue · Quarterly

$21.9B

Q1 2025+2.4%vs Q1 2024
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Johnson & Johnson · $19.9B total across 2 segments · Q1 2023

  • Innovative Medicine
    $13.2B+8.8%
  • MedTech
    $6.78B+3.0%

Forward guidance

J&J raised its quarterly dividend to $1.30 and continues Innovative Medicine and MedTech investment; no quarterly EPS guide disclosed.

Tailwinds

  • Dividend increase signals cash-flow confidence.
  • Intra-Cellular acquisition expands neuroscience portfolio.

Headwinds

  • IRA pricing and patent cliffs pressure pharma margins.
  • Large one-time items can distort quarterly GAAP earnings.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+0.4%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+0.8%

Avg return

30 days after

54%

37 / 69 earnings

Positive

+7.2%

Q2 2023

Best reaction

-4.1%

Q4 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.0%-1.6%-3.8%
Q4 2025-0.4%+1.5%+11.1%
Q3 2025+0.1%+1.2%+2.3%
Q2 2025+0.9%+2.0%+3.1%
Q1 2025-0.5%+2.0%-3.1%
Q4 2024-1.9%+3.2%+9.6%
Q3 2024+1.7%+2.2%-6.0%
Q2 2024+2.9%+2.1%+5.5%
Q1 2024-1.9%+0.2%+4.5%
Q4 2023-2.2%-1.8%-1.2%
Q3 2023-3.0%-2.9%-4.7%
Q2 2023+7.2%+8.6%+8.7%
Q1 2023-1.9%-1.8%-4.3%
Q4 2022+0.7%-0.0%-6.3%
Q3 2022-1.1%+1.3%+5.0%
Q2 2022-2.0%-1.2%-4.3%
Q1 2022+3.5%+2.2%-2.1%
Q4 2021+3.3%+5.4%-3.0%
Q3 2021+2.3%+2.2%+1.4%
Q2 2021+0.9%+2.0%+6.5%
Q1 2021+2.4%+1.7%+5.2%
Q4 2020+1.1%-1.7%-1.9%
Q3 2020-2.5%-2.5%-2.3%
Q2 2020+0.7%+1.0%-0.0%
Q1 2020+5.6%+8.8%+5.6%
Q4 2019-0.5%-0.3%+0.4%
Q3 2019+3.4%-2.3%+0.2%
Q2 2019-2.1%-3.3%-3.1%
Q1 2019+1.5%+0.7%+1.2%
Q4 2018-1.4%-1.9%+3.6%
Q3 2018+4.1%+3.8%+7.9%
Q2 2018+2.5%+0.9%+6.2%
Q1 2018-3.1%-3.9%-6.0%
Q4 2017-4.1%-1.9%-12.3%
Q3 2017+3.3%+4.6%+2.0%
Q2 2017+2.3%+2.4%+0.7%
Q1 2017-3.5%-3.1%+1.0%
Q4 2016-1.0%-0.5%+6.8%
Q3 2016-3.3%-4.3%-1.6%
Q2 2016+1.6%+1.5%-2.0%
Q1 2016+2.4%
Q4 2015+6.0%
Q3 2015-1.5%
Q2 2015+0.1%
Q1 2015+0.0%
Q4 2014-2.1%
Q3 2014-0.9%
Q2 2014-3.0%
Q1 2014+1.7%
Q4 2013-0.8%
Q3 2013+1.5%
Q2 2013-0.3%
Q1 2013+2.7%
Q4 2012-0.5%
Q3 2012+3.5%
Q2 2012+1.3%
Q1 2012-1.1%
Q4 2011+2.0%
Q3 2011-0.6%
Q2 2011-1.5%
Q1 2010+2.1%
Q1 2011-0.6%
Q4 2007+0.7%
Q4 2010+0.7%
Q3 2010+1.8%
Q3 2008+1.8%
Q4 2008-1.1%
Q2 2008-1.1%
Q2 2010-1.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro